Tag: blood brain barrier
-
![Stocks to Watch: Lexaria Bioscience (LEXX.Q) sees gains]()
Stocks to Watch: Lexaria Bioscience (LEXX.Q) sees gains
Special Delivery Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of orally-delivered drugs, DehydraTECH has demonstrated effectiveness in improving delivery through human skin for the potential development of topically-administered products such as patches. Through various animal studies evaluating the quantity…
-
![Bioasis Technologies (BTI.V): To Invest or Not?]()
Bioasis Technologies (BTI.V): To Invest or Not?
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary…
-
![Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)]()
Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical…
-
![Bioasis Technologies (BTI.V) and the painful price of private sector science]()
Bioasis Technologies (BTI.V) and the painful price of private sector science
Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…
